Craneware
Market Cap
UK£619.5m
Last Updated
2020/01/17 20:57 UTC
Data Sources
Company Financials +
Executive Summary
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States.
Rewards
Risk Analysis
No risks detected for CRW from our risk checks.
Snowflake Analysis
Flawless balance sheet with moderate growth potential.
Similar Companies
Share Price & News
How has Craneware's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CRW has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-1.5%
CRW
-0.3%
GB Healthcare Services
1.4%
GB Market
1 Year Return
-9.8%
CRW
7.1%
GB Healthcare Services
12.4%
GB Market
Return vs Industry: CRW underperformed the UK Healthcare Services industry which returned 5.7% over the past year.
Return vs Market: CRW underperformed the UK Market which returned 12.7% over the past year.
Shareholder returns
| CRW | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.5% | -0.3% | 1.4% |
| 30 Day | 4.0% | 1.5% | 2.0% |
| 90 Day | 10.6% | 8.6% | 8.8% |
| 1 Year | -8.9%-9.8% | 8.7%7.1% | 18.3%12.4% |
| 3 Year | 83.2%76.9% | 46.9%38.5% | 23.8%8.0% |
| 5 Year | 406.4%370.4% | 91.1%74.3% | 41.8%8.9% |
Price Volatility Vs. Market
How volatile is Craneware's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is Craneware plc (LON:CRW) A Smart Pick For Income Investors?3 weeks ago | Simply Wall St
Investors Who Bought Craneware (LON:CRW) Shares Five Years Ago Are Now Up 383%1 month ago | Simply Wall St
Don't Sell Craneware plc (LON:CRW) Before You Read ThisValuation
Is Craneware undervalued compared to its fair value and its price relative to the market?
54.3x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CRW (£23.75) is trading above our estimate of fair value (£9.89)
Significantly Below Fair Value: CRW is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CRW is poor value based on its PE Ratio (55x) compared to the Healthcare Services industry average (34x).
PE vs Market: CRW is poor value based on its PE Ratio (55x) compared to the UK market (18.5x).
Price to Earnings Growth Ratio
PEG Ratio: CRW is poor value based on its PEG Ratio (5.6x)
Price to Book Ratio
PB vs Industry: CRW is overvalued based on its PB Ratio (13.6x) compared to the GB Healthcare Services industry average (4x).
Next Steps
Future Growth
How is Craneware forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
9.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRW's forecast earnings growth (9.9% per year) is above the savings rate (0.5%).
Earnings vs Market: CRW's earnings (9.9% per year) are forecast to grow slower than the UK market (11.7% per year).
High Growth Earnings: CRW's earnings are forecast to grow, but not significantly.
Revenue vs Market: CRW's revenue (8.1% per year) is forecast to grow faster than the UK market (3.6% per year).
High Growth Revenue: CRW's revenue (8.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRW's Return on Equity is forecast to be high in 3 years time (29.6%)
Next Steps
Past Performance
How has Craneware performed over the past 5 years?
14.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRW has high quality earnings.
Growing Profit Margin: CRW's current net profit margins (21%) are lower than last year (23.6%).
Past Earnings Growth Analysis
Earnings Trend: CRW's earnings have grown by 14.5% per year over the past 5 years.
Accelerating Growth: CRW's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CRW had negative earnings growth (-5.1%) over the past year, making it difficult to compare to the Healthcare Services industry average (8%).
Return on Equity
High ROE: CRW's Return on Equity (25%) is considered high.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Craneware's financial position?
Financial Position Analysis
Short Term Liabilities: CRW's short term assets ($66.4M) exceed its short term liabilities ($46.5M).
Long Term Liabilities: CRW has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: CRW is debt free.
Reducing Debt: CRW has not had any debt for past 5 years.
Debt Coverage: CRW has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CRW has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: CRW has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if CRW's debt is covered by short term assets.
Next Steps
Dividend
What is Craneware's current dividend yield, its reliability and sustainability?
1.08%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: CRW's dividend (1.07%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.83%).
High Dividend: CRW's dividend (1.07%) is low compared to the top 25% of dividend payers in the UK market (4.95%).
Stability and Growth of Payments
Stable Dividend: CRW's dividend payments have been volatile in the past 10 years.
Growing Dividend: CRW's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (58.9%), CRW's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: CRW's dividends in 3 years are forecast to be covered by earnings (52.6% payout ratio).
Next Steps
Management
What is the CEO of Craneware's salary, the management and board of directors tenure and is there insider trading?
9.0yrs
Average management tenure
CEO
Keith Neilson (50yo)
21yrs
Tenure
US$443,272
Compensation
Mr. Keith Neilson co-founded Craneware PLC in 1999 and has served as its Chief Executive Officer ever since. Keith’s direction has helped Craneware to win multiple prestigious awards in such areas as inter ...
CEO Compensation Analysis
Compensation vs Market: Keith's total compensation ($USD443.27K) is below average for companies of similar size in the UK market ($USD1.13M).
Compensation vs Earnings: Keith's compensation has been consistent with company performance over the past year.
Management Age and Tenure
9.0yrs
Average Tenure
50yo
Average Age
Experienced Management: CRW's management team is seasoned and experienced (9 years average tenure).
Board Age and Tenure
6.2yrs
Average Tenure
59yo
Average Age
Experienced Board: CRW's board of directors are considered experienced (6.2 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Executive Officer Co-Founder |
| Shares | 4,527 |
| Max Price | UK£22.00 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Non-Executive Director |
| Shares | 547 |
| Max Price | UK£22.00 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Non-Executive Director |
| Shares | 1,095 |
| Max Price | UK£22.00 |
| Entity | Individual |
| Shares | 1,500 |
| Max Price | UK£22.00 |
| Entity | Individual |
| Role | Lead Director Senior Independent Non-Executive Director |
| Shares | 1,095 |
| Max Price | UK£22.00 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Craig Preston (48yo)
CFO, Company Secretary & Executive Director
- Tenure: 11.3yrs
- Compensation: US$336.69k
Keith Neilson (50yo)
Co-Founder
- Tenure: 21yrs
- Compensation: US$443.27k
Derek Paterson (51yo)
Chief Information Officer
- Tenure: 19.3yrs
Issy Urquhart
Chief People Officer
- Tenure: 4.1yrs
Karen Bowden
Executive Vice President of Customer Management
- Tenure: 19yrs
Mark Montgomery
Chief Marketing Officer
- Tenure: 6.3yrs
Seth Droe
Executive Vice President of Sales
- Tenure: 6.7yrs
Marty Smith
Chief Technology Officer
Eric Carter
Chief Legal Officer
- Tenure: 2.3yrs
Board Members
Ron Verni (71yo)
Senior Independent Non-Executive Director
- Compensation: US$60.41k
Russ Rudish (66yo)
Independent Non-Executive Director
- Tenure: 5.4yrs
- Compensation: US$52.64k
Will Whitehorn (59yo)
Chairman of the Board
Craig Preston (48yo)
CFO, Company Secretary & Executive Director
- Tenure: 11.3yrs
- Compensation: US$336.69k
Colleen Blye (59yo)
Independent Non-Executive Director
- Tenure: 6.2yrs
- Compensation: US$54.47k
Keith Neilson (50yo)
Co-Founder
- Tenure: 21yrs
- Compensation: US$443.27k
Company Information
Craneware plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Craneware plc
- Ticker: CRW
- Exchange: AIM
- Founded: 1999
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: UK£619.478m
- Shares outstanding: 26.47m
- Website: https://public.craneware.com
Number of Employees
Location
- Craneware plc
- 1 Tanfield
- Edinburgh
- EH3 5DA
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CRW | AIM (London Stock Exchange AIM Market) | Yes | Ordinary Shares | GB | GBP | Sep 2007 |
| CRWR.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Sep 2007 |
Biography
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company offers patient engagement solutions, such as InSight Medical Necessity, a software-as-a-service (SaaS) solution that provides medical necessity validation for United States payers and advance beneficiary notice creation; and Trisus Patient Payment, which provides hospitals and health systems to modernize patient payment. It also provides charge capture and pricing solutions, such as Chargemaster Toolkit, Chargemaster Toolkit Discovery Viewer, and Chargemaster Toolkit Corporate Discovery Viewer for capturing optimal legitimate reimbursement for providers; Physician Revenue Toolkit, a SaaS solution for managing physician group KPIs, charges, codes, RVUs, fee schedules, and related information; Pricing Analyzer, a SaaS solution that simplifies the price modelling process; Reference Plus, a SaaS solution to perform Chargemaster analysis; Pharmacy ChargeLink, a solution to enhance charge capture, pricing, and cost management; Trisus Supply, a solution that utilizes data to identify data gaps between the systems; and supporting modules, including Online Reference Toolkit, interface scripting module, and supplies assistant. In addition, the company provides Trisus Claims Informatics, a software that automates claim and coding reviews; InSight Audit, a Web-based audit management tool for healthcare organizations to manage government and commercial audits; and InSight Denials to analyze, track, trend, and report on denial data. Further, it provides Trisus Healthcare Intelligence, a cost analytics and resource efficiency platform; consulting and professional services; and sales and marketing, product development, and software development services. Craneware plc was founded in 1999 and is headquartered in Edinburgh, the United Kingdom.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/17 20:57 |
| End of Day Share Price | 2020/01/17 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.